Myasthenia Gravis Drug Gets FDA Nod

Myasthenia Gravis Drug Gets FDA Nod

The US Food and Drug Administration (FDA) has approved rozanolixizumab (Rystiggo) to treat adults with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody, the drug’s manufacturer, UCB, has announced. gMG is…

Read More